# TYK2 Inhibition in Paradoxical Psoriasis

> **NCT06281106** · PHASE2,PHASE3 · TERMINATED · sponsor: **Prof Curdin Conrad** · enrollment: 2 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Deucravacitinib

## Key facts

- **NCT ID:** NCT06281106
- **Lead sponsor:** Prof Curdin Conrad
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-06-20
- **Primary completion:** 2025-03-20
- **Final completion:** 2025-03-20
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** External research funds were canceled, so study could unforunately not be continued
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06281106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06281106, "TYK2 Inhibition in Paradoxical Psoriasis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06281106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*